Key interactions of the mutant HIV-1 reverse transcriptase/efavirenz: an evidence obtained from ONIOM method

被引:13
|
作者
Boonsri, Pornthip [1 ,2 ,3 ]
Kuno, Mayuso [4 ]
Hannongbua, Supa [1 ,2 ,3 ]
机构
[1] Kasetsart Univ, Fac Sci, Dept Chem, Bangkok 10900, Thailand
[2] Kasetsart Univ, Ctr Nanotechnol KU, Bangkok 10900, Thailand
[3] Kasetsart Univ, NANOTEC Ctr Excellence, Bangkok 10900, Thailand
[4] Srinakharinwirot Univ, Fac Sci, Dept Chem, Bangkok 10110, Thailand
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; QUANTUM-CHEMICAL CALCULATIONS; WILD-TYPE; K103N MUTANT; CRYSTAL-STRUCTURES; EFAVIRENZ DMP-266; STRUCTURAL BASIS; DRUG-RESISTANCE; BINDING-ENERGY; HIGHLY POTENT;
D O I
10.1039/c1md00162k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two-layered ONIOM calculations were performed in order to compare the binding of efavirenz (EFV) to the HIV-1 RI binding pocket of both wild type (WT) and K103N enzymes. The K103N mutation reduces the binding affinity of the inhibitor by 5.81 kcal mol(-1) as obtained from the ONIOM2 (B3LYP/6-31G(d,p):PM3) method. These indicate that the loss of binding energy to K103N mutation can attribute to a weakened attractive interaction between the drug and residues surrounding in the binding pocket. The deformation of the K103N binding pocket requires more energy for structural rearrangement than that of the WT by approximately 4.0 kcal mol(-1). Moreover, the pairwise energies perfectly demonstrate that the K103N mutation affects on the loss of the interaction energy. In addition, the main influences are due to residues surrounding in the binding pocket; K101, K102, S105, V179, W229, P236 and E138. In particular, two residues; K101 and S105, established hydrogen bondings with the inhibitor. ONIOM calculations, resulting in the details of binding energy, interaction energy and deformation energy can be used to identify the key interaction and structural requirements of more potent HIV-1 RT inhibitor.
引用
收藏
页码:1181 / 1187
页数:7
相关论文
共 50 条
  • [41] An overview on HIV-1 reverse transcriptase inhibitors
    Ravichandran, Shalini
    Veerasamy, Ravichandran
    Raman, Saraswathi
    Krishnan, Palamadai Neelakandam
    Agrawal, Ram Kishore
    DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES, 2008, 3 (04) : 171 - 187
  • [42] Interplay of drugs and drug-resistant reverse transcriptase on HIV-1 mutant frequencies
    Mansky, LM
    Gajary, LC
    ANTIVIRAL THERAPY, 2002, 7 : S44 - S44
  • [43] PROCESSIVITY OF A RECOMBINANT C-TERMINAL MUTANT OF HIV-1 REVERSE-TRANSCRIPTASE
    HUANG, SC
    MOEN, LK
    FASEB JOURNAL, 1994, 8 (07): : A1333 - A1333
  • [44] Low levels of reverse transcriptase associated with one integrase defective mutant of HIV-1
    Cara, A
    Cereseto, A
    Fiorentini, S
    Gusella, L
    Reitz, MS
    FUNDAMENTAL AND CLINICAL IMMUNOLOGY, 1996, 4 (02): : 61 - 66
  • [45] Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase
    Wainberg, MA
    Drosopoulos, WC
    Salomon, H
    Hsu, M
    Borkow, G
    Parniak, MA
    Gu, ZX
    Song, QB
    Manne, J
    Islam, S
    Castriota, G
    Prasad, VR
    SCIENCE, 1996, 271 (5253) : 1282 - 1285
  • [46] ENHANCEMENT OF HIV-1 PROTEINASE ACTIVITY BY HIV-1 REVERSE-TRANSCRIPTASE
    GOOBARLARSSON, L
    LUUKKONEN, BGM
    UNGE, T
    SCHWARTZ, S
    UTTER, G
    STRANDBERG, B
    OBERG, B
    VIROLOGY, 1995, 206 (01) : 387 - 394
  • [47] Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase
    Udier-Blagovic, M
    Watkins, EK
    Tirado-Rives, J
    Jorgensen, WL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (19) : 3337 - 3340
  • [48] Murine leukemia virus reverse transcriptase:: Structural comparison with HIV-1 reverse transcriptase
    Cote, Marie L.
    Roth, Monica J.
    VIRUS RESEARCH, 2008, 134 (1-2) : 186 - 202
  • [49] ONIOM DFT/PM3 calculations on the interaction between dapivirine and HIV-1 reverse transcriptase, a theoretical study
    Liang, Yong-Hong
    Chen, Fen-Er
    DRUG DISCOVERIES AND THERAPEUTICS, 2007, 1 (01): : 57 - 60
  • [50] Insights into Biophysical Methods to Study Interactions Between HIV-1 Reverse Transcriptase and Non-nucleoside Reverse Transcriptase Inhibitors
    Dumond, Julien
    Tronchet, Jean-Marcel J.
    Serge, Kirkiacharian
    Seman, Michel
    Reboud-Ravaux, Michele
    LETTERS IN DRUG DESIGN & DISCOVERY, 2020, 17 (06) : 818 - 825